GlaxoSmithKline forecast on Wednesday that 2019 sales of its shingles vaccine would be more than 1 billion pounds ($1.3 billion) but the British drugmaker’s shares slipped on concerns about its pharmaceutical business and free cash flow.
Powered by WPeMatico